Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study

Table 3 A comparison of the clinical outcomes between sepsis and no-sepsis groups (n = 156)

Variables	Sepsis (n = 71)	No sepsis (n = 85)	p-value
Clinical outcomes
Severity of COVID-19			< 0.001**^a
Moderate illness	4 (5.6%)	55 (64.7%)
Severe illness	11 (15.5%)	30 (35.3%)
Critical illness	56 (78.9%)	0 (0.0%)
Hospital days	27.54 ± 19.53	16.02 ± 7.78	< 0.001**^c
Organ dysfunction
Circulation dysfunction	9 (12.7%)	0 (0%)	0.001*^b
Hepatobiliary dysfunction	7 (9.9%)	3 (3.5%)	0.187^b
Neurologic dysfunction	4 (5.6%)	1 (1.2%)	0.178^b
Respiratory dysfunction	58 (81.7%)	0 (0%)	< 0.001**^b
Renal dysfunction	21 (29.6%)	2 (2.4%)	< 0.001**^b
Hematologic dysfunction	28 (39.4%)	12 (14.1%)	< 0.001**^a
Septic shock	6 (8.5%)	0 (0%)	0.008*^b
48-h SOFA score	4.28 ± 1.86	0.21 ± 0.41	< 0.001**^c
Survival	46 (64.8%)	85 (100.0%)	< 0.001**^a

COVID-19 coronavirus disease, SOFA Sequential Organ Failure Assessment
*p < 0.05; **p < 0.001
^aA Chi-square test was used for comparison analysis
^bFisher’s exact test was used for comparison analysis
^cAn independent t-test was used for continuous variables between sepsis and no-sepsis groups

ISSN: 2047-783X